StemRIM Wins Patent for SR-GT1 Stem Cell Gene Therapy

MT Newswires Live03-02

StemRIM (TYO:4599) said a patent has been granted for technology underpinning its stem cell gene therapy candidate SR-GT1, aimed at treating dystrophic epidermolysis bullosa, according to a Monday filing on the Tokyo Stock Exchange.

The patent, filed by Osaka University, covers the use of genetically modified cells administered directly into patients' blisters as a treatment approach for the rare hereditary skin disorder.

Dystrophic epidermolysis bullosa is caused by abnormalities in type VII collagen, which binds the epidermis and dermis.

StemRIM's approach involves collecting mesenchymal stem cells from patients' blisters, introducing a functional type VII collagen gene, and re-administering the modified cells to affected areas. The cells are designed to engraft in the skin and provide sustained collagen production.

The investigational therapy is being manufactured with support from the Japan Agency for Medical Research and Development, with preparations under way for a physician-led clinical trial.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2616369543?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-02 18:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2616369543","market":"nz","top_or_hot":-1,"title":"StemRIM Wins Patent for SR-GT1 Stem Cell Gene Therapy","media":"MT Newswires Live","content":"<html><body><p> StemRIM (TYO:4599) said a patent has been granted for technology underpinning its stem cell gene therapy candidate SR-GT1, aimed at treating dystrophic epidermolysis bullosa, according to a Monday filing on the Tokyo Stock Exchange.</p><p>The patent, filed by Osaka University, covers the use of genetically modified cells administered directly into patients' blisters as a treatment approach for the rare hereditary skin disorder.</p><p>Dystrophic epidermolysis bullosa is caused by abnormalities in type VII collagen, which binds the epidermis and dermis.</p><p>StemRIM's approach involves collecting mesenchymal stem cells from patients' blisters, introducing a functional type VII collagen gene, and re-administering the modified cells to affected areas. The cells are designed to engraft in the skin and provide sustained collagen production.</p><p>The investigational therapy is being manufactured with support from the Japan Agency for Medical Research and Development, with preparations under way for a physician-led clinical trial.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>StemRIM Wins Patent for SR-GT1 Stem Cell Gene Therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStemRIM Wins Patent for SR-GT1 Stem Cell Gene Therapy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-03-02 18:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> StemRIM (TYO:4599) said a patent has been granted for technology underpinning its stem cell gene therapy candidate SR-GT1, aimed at treating dystrophic epidermolysis bullosa, according to a Monday filing on the Tokyo Stock Exchange.</p><p>The patent, filed by Osaka University, covers the use of genetically modified cells administered directly into patients' blisters as a treatment approach for the rare hereditary skin disorder.</p><p>Dystrophic epidermolysis bullosa is caused by abnormalities in type VII collagen, which binds the epidermis and dermis.</p><p>StemRIM's approach involves collecting mesenchymal stem cells from patients' blisters, introducing a functional type VII collagen gene, and re-administering the modified cells to affected areas. The cells are designed to engraft in the skin and provide sustained collagen production.</p><p>The investigational therapy is being manufactured with support from the Japan Agency for Medical Research and Development, with preparations under way for a physician-led clinical trial.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4197","symbol_name":"燃气公用事业","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2616369543","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2616369543","pubTimestamp":1772445654,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"StemRIM (TYO:4599) said a patent has been granted for technology underpinning its stem cell gene therapy candidate SR-GT1, aimed at treating dystrophic epidermolysis bullosa, according to a Monday fil","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4197":"燃气公用事业","SR":"SPIRE"},"translate_title":"StemRIM赢得SR-GT1干细胞基因疗法专利","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SR":1.5},"content_text":"StemRIM (TYO:4599) said a patent has been granted for technology underpinning its stem cell gene therapy candidate SR-GT1, aimed at treating dystrophic epidermolysis bullosa, according to a Monday filing on the Tokyo Stock Exchange.The patent, filed by Osaka University, covers the use of genetically modified cells administered directly into patients' blisters as a treatment approach for the rare hereditary skin disorder.Dystrophic epidermolysis bullosa is caused by abnormalities in type VII collagen, which binds the epidermis and dermis.StemRIM's approach involves collecting mesenchymal stem cells from patients' blisters, introducing a functional type VII collagen gene, and re-administering the modified cells to affected areas. The cells are designed to engraft in the skin and provide sustained collagen production.The investigational therapy is being manufactured with support from the Japan Agency for Medical Research and Development, with preparations under way for a physician-led clinical trial.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2616369543","isCrawlerRequest":true}